A detailed history of Captrust Financial Advisors transactions in Exact Sciences Corp stock. As of the latest transaction made, Captrust Financial Advisors holds 9,433 shares of EXAS stock, worth $465,329. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,433
Previous 7,579 24.46%
Holding current value
$465,329
Previous $320,000 100.63%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$42.43 - $70.83 $78,665 - $131,318
1,854 Added 24.46%
9,433 $642,000
Q2 2024

Aug 14, 2024

SELL
$41.33 - $74.26 $38,726 - $69,581
-937 Reduced 11.0%
7,579 $320,000
Q1 2024

May 15, 2024

SELL
$56.27 - $73.77 $501,703 - $657,733
-8,916 Reduced 51.15%
8,516 $588,000
Q4 2023

Feb 14, 2024

BUY
$59.06 - $75.72 $167,435 - $214,666
2,835 Added 19.42%
17,432 $1.29 Million
Q3 2023

Nov 14, 2023

SELL
$65.94 - $99.04 $157,794 - $237,002
-2,393 Reduced 14.08%
14,597 $995,000
Q2 2023

Aug 14, 2023

BUY
$62.68 - $95.05 $25,134 - $38,115
401 Added 2.42%
16,990 $1.6 Million
Q1 2023

May 15, 2023

BUY
$47.19 - $70.77 $83,762 - $125,616
1,775 Added 11.98%
16,589 $1.12 Million
Q4 2022

Feb 15, 2023

BUY
$30.35 - $53.15 $33,961 - $59,474
1,119 Added 8.17%
14,814 $733,000
Q3 2022

Nov 16, 2022

BUY
$31.97 - $49.37 $92,585 - $142,975
2,896 Added 26.82%
13,695 $445,000
Q2 2022

Aug 23, 2022

SELL
$35.61 - $76.23 $175,165 - $374,975
-4,919 Reduced 31.3%
10,799 $425,000
Q2 2022

Aug 16, 2022

BUY
$35.61 - $76.23 $277,651 - $594,365
7,797 Added 98.43%
15,718 $619,000
Q1 2022

May 16, 2022

BUY
$57.56 - $82.54 $40,234 - $57,695
699 Added 9.68%
7,921 $554,000
Q4 2021

Feb 14, 2022

BUY
$72.5 - $100.68 $37,410 - $51,950
516 Added 7.69%
7,222 $562,000
Q3 2021

Nov 16, 2021

BUY
$90.24 - $124.05 $39,254 - $53,961
435 Added 6.94%
6,706 $640,000
Q2 2021

Aug 16, 2021

SELL
$93.66 - $139.27 $13,955 - $20,751
-149 Reduced 2.32%
6,271 $780,000
Q1 2021

May 17, 2021

BUY
$116.57 - $155.01 $52,456 - $69,754
450 Added 7.54%
6,420 $846,000
Q4 2020

Feb 16, 2021

BUY
$99.61 - $142.12 $33,767 - $48,178
339 Added 6.02%
5,970 $791,000
Q3 2020

Nov 17, 2020

SELL
$72.92 - $102.01 $160,424 - $224,422
-2,200 Reduced 28.09%
5,631 $592,000
Q2 2020

Aug 14, 2020

SELL
$55.75 - $92.75 $2,731 - $4,544
-49 Reduced 0.62%
7,831 $685,000
Q1 2020

May 15, 2020

SELL
$37.9 - $104.44 $9,588 - $26,423
-253 Reduced 3.11%
7,880 $440,000
Q4 2019

Feb 14, 2020

BUY
$77.66 - $99.74 $491,199 - $630,855
6,325 Added 349.83%
8,133 $777,000
Q3 2019

Nov 14, 2019

BUY
$90.37 - $122.49 $2,349 - $3,184
26 Added 1.46%
1,808 $163,000
Q2 2019

Aug 13, 2019

BUY
$89.51 - $118.04 $71,966 - $94,904
804 Added 82.21%
1,782 $210,000
Q1 2019

May 15, 2019

BUY
$61.98 - $96.5 $54,418 - $84,727
878 Added 878.0%
978 $85,000
Q3 2017

Feb 16, 2018

BUY
$37.05 - $47.12 $3,704 - $4,712
100
100 $5,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $8.73B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.